MMSI Stock Cash Flow Statements

Merit Medical Systems Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Merit Medical Systems Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-09-30	2005-06-30	2005-03-31	2004-09-30

cash flows from operating activities:
net income	32,581,000	30,147,000	27,947,000	28,444,000	35,726,000	28,240,000	27,629,000	25,834,000	20,245,000	20,703,000	33,401,000	15,272,000	15,298,000	10,545,000	20,613,000	11,967,000	4,916,000	10,958,000	15,378,000	-3,009,000	-19,058,000	-3,154,000	-4,205,000	-3,398,000	6,859,000	6,195,000	9,189,000	16,618,000	10,941,000	5,269,000	6,806,000	-3,569,000	9,483,000	14,803,000	7,506,000	974,000	7,290,000	4,351,000	6,409,000	4,818,000	7,401,000	5,174,000	8,671,000	7,764,000	3,716,000	2,823,000	6,540,000	5,607,000	3,752,000	671,000	641,000	4,970,000	4,563,000	6,872,000	6,639,000	4,210,000	-1,973,000	5,715,000	4,508,000	5,067,000	6,085,000	5,841,000	5,537,000	5,200,000	5,818,000	4,317,000	4,728,000	4,295,000	3,596,000	2,969,000	3,053,000	3,325,000	3,522,000	2,401,000	3,327,000	4,682,000	4,074,000	4,187,566
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	31,021,000	29,292,000	28,616,000	26,403,000	24,091,000	23,599,000	23,626,000	24,043,000	21,779,000	20,537,000	20,492,000	20,410,000	20,436,000	20,466,000	20,893,000	20,756,000	21,017,000	21,400,000	23,612,000	23,418,000	23,720,000	23,320,000	23,593,000	23,497,000	22,662,000	22,348,000	19,110,000	17,657,000	17,495,000	15,284,000	14,194,000	13,679,000	12,950,000	12,759,000	12,161,000	11,889,000	10,000,000	9,705,000	9,680,000	9,489,000	9,188,000	9,068,000	9,210,000	9,126,000	8,891,000	8,702,000	8,616,000	8,197,000	8,046,000	7,683,000	5,810,000	4,944,000	4,778,000	4,678,000	4,794,000	4,291,000	3,892,000	3,383,000	3,290,000	3,291,000	3,270,000	3,029,000	2,681,000	2,567,000	2,548,000	2,565,000	2,554,000	2,350,000	2,297,000	2,243,000	2,197,000	2,080,000	2,035,000	1,963,000	1,449,000	1,273,000	1,213,000	1,188,875
gain on disposition of business
loss on sale or abandonment of property and equipment	228,000	87,000	1,275,000	136,000	44,000	35,000	1,077,000	84,000	4,470,000	207,000	184,000	84,000
write-off of certain intangible assets and other long-term assets	50,000	32,000	55,000	121,000	78,000	202,000	45,000	133,000			548,000	0	61,000	1,672,000	0	44,000			8,200,000	20,589,000	3,895,000	3,925,000
amortization of right-of-use operating lease assets	2,782,000	2,984,000	2,980,000	2,980,000	2,941,000	3,122,000	2,686,000	2,686,000	3,273,000	2,662,000	2,575,000	2,698,000	2,537,000	2,584,000	2,777,000	2,867,000	3,004,000	3,070,000	3,224,000	3,183,000	3,205,000	3,134,000	3,030,000	3,352,000	2,910,000	2,964,000
fair value adjustments related to contingent consideration liabilities	143,000	1,023,000	151,000	103,000
amortization of deferred credits	-26,000	-26,000	-26,000	-25,000	-26,000	-26,000	-26,000	-26,000	-26,000	-26,000	-26,000	-27,000	-27,000	-27,000	-27,000	-27,000	-27,000	-27,000	-27,000	-34,000	-34,000	-35,000	-35,000	-34,000	-35,000	-35,000	-36,000	-35,000	-35,000	-36,000	-36,000	-35,000	-36,000	-40,000	-42,000	-43,000	-42,000	-43,000	-42,000	-44,000	-42,000	-43,000	-44,000	-43,000	-43,000	-45,000	-42,000	-33,000	-32,000	-32,000	-34,000	-25,000
amortization and write-off of long-term debt issuance costs	1,414,000	1,414,000
stock-based compensation expense	10,873,000	9,078,000	9,515,000	6,713,000	7,011,000	5,234,000	5,987,000	5,797,000	5,580,000	3,969,000	4,351,000	4,598,000	4,451,000	4,642,000	4,501,000	4,857,000	3,137,000	3,595,000	4,071,000	4,063,000	3,428,000	2,777,000	2,467,000	2,626,000	2,523,000	1,766,000	1,623,000	1,673,000	1,565,000	1,256,000	1,192,000	1,192,000	1,114,000	577,000	593,000	503,000	786,000	624,000	600,000	558,000	565,000	520,000	456,000	341,000	324,000	339,000	395,000	289,000	324,000	459,000	463,000
changes in operating assets and liabilities, net of acquisitions:
trade receivables	250,000	-7,560,000	-4,146,000	-2,639,000	-2,719,000	-4,182,000	-8,064,000	2,128,000	-1,100,000	-4,880,000	-6,053,000	409,000	-5,621,000	-3,851,000	-2,438,000	1,653,000	-2,549,000	-5,284,000	-2,624,000	-2,243,000	11,847,000	3,445,000	-11,114,000	14,420,000	-9,649,000	-11,557,000	-2,040,000	2,465,000	-14,781,000	-13,166,000	-1,881,000	2,285,000	-7,491,000	-5,757,000	-1,650,000	1,293,000	-5,624,000	-835,000	-2,348,000	-731,000	-459,000	-2,334,000	-4,401,000	-2,046,000	-3,037,000	-4,115,000	-2,745,000	1,490,000	-3,717,000	-1,473,000	945,000	-132,000												-1,545,000	159,000	1,505,000		308,000			-2,129,000	-314,000	-313,000	2,813,000
other receivables	3,101,000	-284,000	-1,812,000	-4,171,000	206,000	-705,000	3,469,000	-1,327,000	1,752,000	-1,465,000	-1,515,000	-788,000	603,000	5,854,000	-7,245,000	-2,380,000	-196,000	-597,000	498,000	527,000	30,000	613,000	1,787,000	-355,000	-643,000	1,070,000	-3,009,000	-711,000	68,000	898,000	-3,054,000	-335,000	-542,000	374,000	-2,239,000	1,259,000	759,000	1,367,000	-389,000	-166,000	1,677,000	-735,000	-2,157,000	-132,000	-1,192,000	439,000	-174,000	28,000	123,000	-586,000	-270,000	-41,000			17,000			173,000	171,000		8,000	266,000	78,000	54,000	124,000	253,000
inventories	-1,121,000	-10,599,000	557,000	-5,963,000	3,501,000	-382,000	2,321,000	1,076,000	-12,528,000	-22,974,000	-17,194,000	-15,969,000	-5,589,000	-9,177,000	-14,003,000	-14,365,000	6,581,000	-3,396,000	13,761,000	13,413,000	7,238,000	-4,983,000	-7,742,000	-14,164,000	-3,798,000	-1,340,000	-8,797,000	-12,186,000	-1,801,000	-5,388,000	-7,912,000	-7,762,000	-3,004,000	844,000	-3,876,000	1,623,000	869,000	-2,272,000	-5,681,000	-7,598,000	-3,352,000	3,518,000	1,157,000	-6,459,000	-1,742,000	-2,352,000	-827,000	122,000	890,000	2,149,000	-81,000	-3,354,000			245,000				353,000								2,634,000	1,426,000	588,000	408,000
prepaid expenses and other current assets	-4,616,000	2,041,000	1,576,000	-3,565,000	-3,071,000	765,000	1,353,000	-150,000	-1,308,000	1,386,000	2,388,000	-2,031,000	-848,000	-1,307,000	2,696,000	-2,428,000	-2,752,000	-1,071,000	3,483,000	-2,580,000	1,777,000	-3,126,000	2,620,000	-2,807,000	-1,071,000	19,000	719,000	386,000	-1,882,000	-1,223,000
income tax refund receivables	-5,796,000	2,143,000	5,994,000	-3,909,000	-3,926,000	305,000	8,624,000	-5,105,000	-3,307,000	-270,000	3,665,000	-1,709,000	-200,000	196,000	-221,000	969,000	-208,000	199,000	8,327,000	-1,337,000	-4,854,000	-2,475,000	6,433,000	-4,700,000	-3,538,000	-442,000	98,000	1,280,000	-941,000	-205,000	-868,000	-14,000	644,000	-350,000	-108,000	-358,000	448,000	424,000	-566,000	-140,000	461,000	-539,000	1,000	-14,000	-168,000	192,000																										27,000
other assets	-1,295,000	-176,000	-2,206,000	-892,000	-21,000	-2,947,000	-5,257,000	839,000	-1,479,000	-79,000	-1,191,000	80,000	935,000	833,000	1,968,000	-2,953,000	-765,000	80,000	-2,423,000	-1,216,000	705,000	-577,000	-1,309,000	-987,000	-753,000	-2,092,000	1,685,000	-619,000	-260,000	-491,000	-743,000	-1,492,000	-328,000	-1,172,000	-2,172,000	-829,000	-871,000	109,000	414,000	2,111,000	-2,285,000	-602,000	-260,000	-487,000	206,000	-847,000	-883,000	-110,000	-436,000	-377,000	-309,000				22,000
trade payables	-756,000	4,453,000	4,175,000	607,000	7,052,000	-14,148,000	13,035,000	-13,079,000	-4,290,000	-2,963,000	2,909,000	6,039,000	1,043,000	2,670,000	4,869,000	-4,458,000	1,402,000	4,237,000	3,015,000	1,190,000	-8,212,000	4,340,000	1,480,000	-5,113,000	2,216,000	-878,000	-210,000	169,000	7,358,000	8,409,000	1,293,000	-4,540,000	2,625,000	1,039,000	2,183,000	-3,871,000	-7,547,000	2,400,000	5,028,000	4,516,000	5,138,000	84,000	4,671,000	-1,644,000	2,784,000	-485,000	4,073,000	-4,664,000	2,670,000	-2,084,000	1,916,000	1,892,000				5,326,000	-28,000			-2,806,000	-407,000	1,728,000	1,781,000	-829,000	-91,000	1,392,000					220,000	-286,000	-166,000	537,000	1,448,000	-1,552,000	1,630,000	127,180
accrued expenses	18,007,000	-20,747,000	10,329,000	2,190,000	6,087,000	-8,891,000	-1,885,000	9,696,000	-6,724,000	-3,571,000	-7,518,000	12,105,000	2,542,000	-23,508,000	16,887,000	10,369,000	3,813,000	5,393,000	-17,988,000	2,927,000	21,285,000	-1,621,000	9,514,000	-1,859,000	5,375,000	-3,450,000	4,999,000	240,000	9,862,000	-2,395,000	1,947,000	-3,319,000	4,548,000	3,285,000	1,552,000	-1,346,000	6,975,000	-3,936,000	-1,361,000	2,542,000	1,822,000	2,653,000	1,451,000	1,147,000	671,000	2,868,000	-127,000	3,556,000	-1,425,000	-2,280,000	1,655,000	-1,272,000	2,288,000			549,000	573,000			-977,000	949,000	1,086,000	570,000	541,000	1,045,000	209,000	-433,000	17,000	1,089,000	199,000		-490,000
income taxes payable	-381,000	1,918,000	461,000	1,623,000	-7,520,000	3,651,000	1,746,000	1,465,000	-7,554,000	2,658,000	5,895,000	-2,488,000	-33,000	1,147,000	1,481,000	-740,000	-686,000	-174,000	-1,165,000	-493,000	-537,000	2,109,000	577,000	1,131,000	-1,180,000	-879,000	2,446,000	548,000	-1,596,000	-480,000	785,000	-463,000	-279,000	-22,000	1,634,000	-1,803,000	1,042,000	578,000	-1,847,000	1,137,000	1,532,000	1,377,000	-2,165,000	2,489,000	668,000	91,000	393,000	1,181,000	-1,285,000	-34,000	-613,000	-3,910,000	1,271,000	2,595,000	2,702,000	-1,462,000	309,000	578,000	1,612,000	-1,034,000	-353,000	77,000	2,135,000	1,279,000	-1,444,000	1,855,000	875,000	-234,000	-377,000	1,331,000	1,169,000	593,000	207,000	755,000			964,000	-1,164,004
deferred compensation payable	1,183,000	-580,000	-21,000	630,000	360,000	1,061,000	1,658,000	-909,000	549,000	605,000	477,000	-776,000	-1,242,000	-1,307,000	697,000	359,000	828,000	-581,000	1,412,000	1,202,000	128,000	-789,000	1,359,000	758,000	257,000	1,261,000	-955,000	556,000	435,000	3,000	863,000	594,000	326,000	187,000	212,000	-103,000	908,000	-305,000	-433,000	-524,000	349,000	473,000	158,000	112,000	250,000	282,000	1,012,000	218,000	366,000	281,000	533,000	203,000	-286,000	191,000	219,000	757,000	83,000	-23,000	59,000	334,000	312,000																	188,006
operating lease liabilities	-2,590,000	-3,335,000	-3,127,000	-3,094,000	-3,031,000	-2,931,000	-2,919,000	-2,862,000	-3,474,000	-2,237,000	-2,721,000	-2,797,000	-2,768,000	-2,841,000	-3,045,000	-3,106,000	-3,108,000	-3,151,000	-3,261,000	-3,221,000	-3,232,000	-2,945,000	-3,014,000	-3,074,000	-2,828,000	-3,054,000
other long-term obligations	-1,496,000	-733,000	-1,929,000	164,000	-60,000	2,854,000	-212,000	-74,000	-1,855,000	-389,000	787,000	-796,000	-287,000	574,000	-1,059,000	-62,000	207,000	56,000	-984,000	2,575,000	2,194,000	-179,000	-7,085,000	2,976,000	1,060,000	1,148,000	580,000	-1,202,000	158,000	-337,000	1,936,000	-333,000	117,000	790,000	51,000	-39,000	-136,000	-76,000	1,167,000	-39,000	208,000	433,000	-198,000	318,000	496,000	-50,000	-787,000	-3,485,000	-421,000	294,000	-403,000	-1,046,000	560,000	377,000	39,000								2,000
total adjustments	50,726,000	10,425,000	40,797,000	18,889,000	32,780,000	7,976,000	34,622,000	25,235,000	-2,959,000	-6,158,000	-5,393,000	20,217,000	23,486,000	1,465,000	25,202,000	13,009,000	36,292,000	24,274,000	21,537,000	58,148,000	63,410,000	32,018,000	31,114,000	18,612,000	15,326,000	7,310,000	14,487,000	11,190,000	16,173,000	2,666,000	12,528,000	12,396,000	9,905,000	375,000	9,755,000	9,920,000	6,571,000	7,232,000	6,044,000	11,805,000	13,709,000	14,098,000	13,069,000	3,682,000	8,463,000	5,137,000	11,209,000	13,652,000	7,720,000	2,222,000	14,135,000	337,000	10,538,000			9,929,000	7,733,000	4,076,000	562,000	1,499,000	244,000	1,986,000	3,811,000	-2,050,000	438,000	5,286,000	5,485,000	4,175,000	4,046,000	2,825,000	1,306,000	-91,000	639,000	4,951,000			1,001,000	3,164,670
net cash, cash equivalents, and restricted cash from operating activities	83,307,000	40,572,000	68,744,000	47,333,000	68,506,000	36,216,000	62,251,000	51,069,000	17,286,000	14,545,000	28,008,000	35,489,000	38,784,000	12,010,000

cash flows from investing activities:
capital expenditures for:
property and equipment	-13,751,000	-21,061,000	-3,472,000	-9,359,000	-10,627,000	-11,682,000	-7,139,000	-8,595,000	-5,771,000	-12,785,000	-12,490,000	-15,776,000	-7,237,000	-9,526,000	-8,327,000	-6,795,000	-6,646,000	-6,171,000	-10,398,000	-9,787,000	-11,853,000	-13,950,000	-20,069,000	-22,145,000	-17,704,000	-18,255,000	-16,300,000	-15,465,000	-15,320,000	-16,239,000	-9,101,000	-11,740,000	-7,604,000	-10,178,000	-6,345,000	-5,270,000	-10,231,000	-10,991,000	-11,458,000	-14,135,000	-15,874,000	-9,492,000	-9,919,000	-5,546,000	-10,008,000	-8,708,000	-11,470,000	-17,646,000	-10,428,000	-19,961,000	-15,379,000	-22,109,000
intangible assets	-839,000	-457,000	-765,000	-562,000	-715,000	-861,000	-655,000	-709,000	-776,000	-271,000	-1,266,000	-997,000	-570,000	-342,000	-713,000	-652,000	-777,000	-692,000	-789,000	-709,000	-728,000	-1,062,000	-764,000	-953,000	-754,000	-853,000	-778,000	-479,000	-870,000	-885,000	-650,000	-845,000	-414,000	-668,000	-623,000	-605,000	-507,000	-482,000	-571,000	-510,000	-380,000	-495,000	-346,000	-443,000	-492,000	-433,000
proceeds from the sale of property and equipment			0	3,000			20,000	-20,000	1,000	200,000	2,000	4,000			0	153,000	11,000	873,000	9,000	6,000			658,000	240,000	19,000	3,000	48,000	3,000	1,000	3,000	12,000	6,000	0	3,000	14,000				1,205,000	36,000	3,000	3,000	36,000	41,000	3,000	18,000	41,000	19,000	45,000	8,000	34,000	0				1,000	6,000	3,000	7,000	4,000	8,000										1,000	12,000			0			1,287
proceeds from disposition of business
cash paid for notes receivable and other investments	-7,500,000	-7,117,000
cash paid in acquisitions, net of cash acquired	-121,555,000	-1,000,000				-3,346,000	0	71,000	-136,349,000	-2,000,000	-3,575,000	0			-5,313,000	0	-1,500,000	-358,000	-10,693,000	-160,000			-392,000	-16,256,000	-35,314,000	-1,942,000	-179,019,000	-4,116,000	-18,459,000	-100,195,000	-2,082,000	-48,691,000	-7,348,000	-47,461,000	-5,353,000	-97,008,000	-1,300,000	-21,500,000	-500,000	-9,618,000	-1,000,000	-1,250,000	-1,725,000	-2,752,000
net cash, cash equivalents, and restricted cash from investing activities	-143,351,000	-29,635,000	-214,447,000	-115,668,000	-16,487,000	-22,051,000	-8,343,000	-9,253,000	-142,895,000	-14,856,000	-17,329,000	-16,769,000	-13,431,000	-9,868,000
see condensed notes to consolidated financial statements.
(gain) loss on disposition of business
acquired in-process research and development							0	0			0	0											0	0	500,000	25,000	262,000	76,000			0	12,061,000			61,000	300,000			0												0	2,400,000
deferred income taxes																															-1,014,000	5,000	92,000	-387,000	-1,149,000	46,000	-29,000	170,000	2,494,000	573,000	-79,000	462,000	4,054,000	-203,000	-2,000	21,000	1,372,000	-7,000	-8,000	2,000	535,000	1,214,000	357,000	13,000	93,000				1,000				2,000				-348,000	835,000							394,000	3,000	73,000
changes in operating assets and liabilities, net of acquisitions and divestitures:
prepaid income taxes							-68,000												-127,000						8,000	-53,000	-324,000	-20,000	-28,000	-72,000	-380,000	-139,000	-3,000	-89,000	467,000	55,000	-80,000	-38,000	-1,745,000	0	-95,000	52,000	-74,000	30,000			35,000	-25,000	-9,000	17,000	-369,000
liabilities related to unrecognized tax benefits																																			963,000				1,240,000				768,000	-580,000			383,000				784,000
proceeds (payments) from disposition of business
see notes to consolidated financial statements.
amortization of long-term debt issuance costs				1,477,000	1,477,000	1,477,000		282,000	311,000	151,000	151,000	151,000	151,000	151,000	151,000	151,000	151,000	151,000	151,000	151,000	151,000	151,000	151,000	168,000	201,000	201,000	201,000	201,000	201,000	201,000	171,000	171,000	172,000	171,000	173,000	258,000	264,000	257,000	246,000	247,000	247,000	247,000	246,000	247,000	247,000	247,000	247,000	199,000	200,000	199,000
issuance of note receivables				-500,000	0	-6,162,000
cash paid in acquisitions and investments, net of cash acquired				-105,250,000
adjustments related to contingent consideration liabilities						-117,000		562,000	1,094,000	521,000
cash received for settlement of note receivable
issuance of note receivable																												-250,000
loss on disposition of business												135,000
payments from disposition of business												0
adjustments and payments related to contingent consideration liability												889,000
gain on sales and/or abandonment of property and equipment														94,000																																		112,000
fair value adjustments to contingent consideration														2,600,000	-161,000	1,115,000	1,805,000	402,000	-8,844,000	-4,356,000	343,000	4,897,000
gain on sale of business																			-9,000
loss on sales and/or abandonment of property and equipment															673,000	388,000	270,000	-28,000	856,000	933,000	333,000	37,000	-522,000	-166,000	515,000	288,000		54,000	20,000	351,000																				7,000
long-term income taxes payable
net cash from operating activities															45,815,000	24,976,000	41,208,000	35,232,000	36,915,000	55,139,000	44,352,000	28,864,000	26,909,000	15,214,000	22,185,000	13,505,000	23,676,000	27,808,000	27,114,000	7,935,000	19,334,000	8,827,000	19,388,000	15,178,000	17,261,000	10,894,000	13,861,000	11,583,000	12,453,000	16,623,000	21,110,000	19,272,000	21,740,000	11,446,000	12,179,000	7,960,000	17,749,000	19,259,000	11,472,000	2,893,000	14,776,000	5,307,000	15,101,000	9,004,000	4,603,000	14,139,000	5,760,000	9,791,000	5,070,000	6,566,000	6,329,000	7,827,000	9,348,000	3,150,000	6,256,000	9,603,000	10,213,000	8,470,000	7,642,000	5,794,000	4,359,000	3,234,000	4,161,000	7,352,000			5,075,000	7,352,236
proceeds from sale of business																			0
net cash from investing activities															-14,607,000	-7,294,000	-8,912,000	-6,348,000	-21,871,000	-9,365,000	-12,654,000	-14,762,000	-20,567,000	-39,114,000	-53,753,000	-21,047,000	-196,049,000	-20,307,000	-45,148,000	-117,316,000	-11,821,000	-61,270,000	-15,366,000	-58,304,000	-12,307,000	-102,878,000	-12,038,000	-31,884,000	-11,324,000	-24,227,000	-17,057,000	-9,411,000	-9,617,000	-5,516,000	-11,947,000	-9,123,000	-18,503,000	-18,109,000	-10,650,000	-21,347,000	-184,953,000	-26,921,000
cash received for settlement of current note receivable																			0	0	0	250,000
changes in operating assets and liabilities, net of effects from acquisitions:
gain on bargain purchase																															-243,000	778,000	669,000	-12,243,000
write-off of patents and intangible assets																								2,898,000			70,000	658,000	29,000	57,000	902,000	67,000	1,000	18,000	11,000	0			42,000	85,000	0	14,000	67,000			34,000	39,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2019 and 2018
cash flows from financing activities:
proceeds from issuance of common stock																									1,641,000	1,733,000	1,717,000	210,025,000	1,740,000	1,511,000	741,000	2,080,000	2,420,000	138,569,000	849,000	3,631,000	234,000	557,000	744,000	780,000	1,123,000	4,021,000	4,335,000	283,000	2,725,000	803,000	2,570,000	283,000	305,000	571,000	429,000										1,025,000	284,000	101,000			1,725,000						949,000
proceeds from issuance of long-term debt																									82,627,000	43,119,000	258,283,000	59,998,000	63,856,000	256,971,000	45,752,000	54,603,000	13,136,000	83,723,000	16,027,000	109,666,000	38,628,000	55,184,000	42,470,000	44,566,000	33,536,000	31,803,000	35,236,000	37,048,000	35,724,000	36,010,000
payments on long-term debt																									-66,627,000	-54,119,000	-72,033,000	-264,748,000	-36,856,000	-148,971,000	-45,252,000	-18,603,000	-8,636,000	-170,723,000	-19,440,000	-12,971,000	-35,311,000	-34,376,000	-45,095,000	-44,121,000	-36,641,000	-43,415,000	-51,620,000	-45,559,000	-41,790,000	-30,423,000	-68,843,000	-44,724,000	-34,398,000	-17,512,000	-29,650,000
contingent payments related to acquisitions																									-57,000	-554,000	-47,000	-54,000	-115,000	-15,000	-16,000	-15,000	-15,000	-15,000	-19,000	-16,000	-16,000	-167,000	-1,018,000	-14,000	-14,000	-166,000	-12,000	-17,000	-14,000	-24,000	-17,000	-22,000	-19,000	-19,000	-21,000
net cash from financing activities																									17,584,000	-9,821,000	187,920,000	2,239,000	28,625,000	109,496,000	809,000	38,064,000	6,923,000	50,721,000	-2,441,000	98,815,000	3,526,000	21,195,000	-2,747,000	1,504,000	-1,715,000	-7,277,000	-11,757,000	-8,238,000	-3,287,000	6,314,000	-946,000	-5,239,000	2,911,000	18,042,000	170,482,000															1,973,000				877,000		1,104,000	640,000	800,000	1,892,000	1,117,000	506,000	455,786
effect of exchange rates on cash																									-356,000	-474,000	-143,000	-1,297,000	-1,250,000	1,720,000	652,000	66,000	266,000	-302,000	-660,000	0	-24,000	91,000	-64,000	-143,000	-144,000	-31,000	551,000	-655,000	-135,000	-19,000	44,000	61,000	393,000	-290,000	-51,000														207,000	158,000		184,000	22,000	86,000		1,000	119,000	11,000
net increase in cash and cash equivalents																									-14,340,000	-17,837,000	15,404,000	8,443,000	9,341,000	1,835,000	8,974,000	-14,313,000	11,211,000	7,293,000	1,853,000	6,831,000	5,325,000	985,000			2,194,000	2,553,000			-3,190,000	5,132,000					254,000																							4,369,000				-1,431,059
cash and cash equivalents:
beginning of period																									0	67,359,000		0	0	32,336,000		0	0	19,171,000		0	0	4,177,000		0	0	7,355,000		0	0	7,459,000		0	0	9,719,000											0	0	34,030,000		0	17,574,000		0	0	9,838,000		0	0	4,645,000	0	0	33,037,000	-83
end of period																									-14,340,000	49,522,000		8,443,000	9,341,000	34,171,000		-14,313,000	11,211,000	26,464,000		6,831,000	5,325,000	5,162,000		-6,243,000	2,194,000	9,908,000		-2,963,000	-3,190,000	12,591,000		-4,028,000	4,126,000	9,017,000											890,000	-11,557,000	16,430,000		2,999,000	23,757,000		2,918,000	-364,000	9,645,000		-639,000	-1,370,000	9,014,000	-6,859,000	-9,782,000	28,617,000	-1,431,142
supplemental disclosures of cash flow information
cash paid during the period for:
interest																									3,073,000	2,721,000	2,306,000	2,304,000	3,331,000	2,383,000	1,754,000	1,567,000	1,643,000	2,743,000	2,649,000	3,311,000	1,534,000	1,378,000	1,560,000	1,434,000	2,025,000	1,254,000	1,810,000	2,235,000	2,325,000	2,644,000	2,496,000	2,411,000	1,477,000	1,493,000	196,000										29,000	9,000	2,000		3,000	2,000		-1,000	1,000	3,000		2,000	3,000	2,000	13,000	0	5,000	363
income taxes																									6,922,000	1,934,000	2,623,000	928,000	3,331,000	1,810,000	2,020,000	1,351,000	1,107,000	1,571,000	81,000	657,000	1,152,000	428,000	504,000	696,000	1,278,000	931,000	610,000	768,000	1,129,000	782,000	-1,289,000	953,000	668,000	403,000	648,000										2,854,000	3,063,000	463,000		4,733,000	2,876,000		1,668,000	1,634,000	218,000		1,555,000	1,428,000	36,000	1,260,000	2,427,000	1,221,000	2,179,248
supplemental disclosures of non-cash investing and financing activities
property and equipment purchases in accounts payable																									-1,257,000	4,588,000	1,931,000	-885,000	2,191,000	1,752,000	598,000	-166,000	804,000	756,000	-311,000	1,212,000	-87,000	1,584,000	878,000	-31,000	609,000	1,743,000	-957,000	420,000	-1,747,000	5,180,000	-1,285,000	-7,032,000	7,018,000	5,354,000	4,943,000										118,000	-113,000	1,689,000
acquisition purchases in accrued expenses and other long-term obligations																															-1,512,000	6,000,000							0												149,000
merit common stock surrendered (0 and 32 shares, respectively) in exchange for exercise of stock options
right-of-use operating lease assets obtained in exchange for operating lease liabilities																									1,765,000	1,162,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2019 and 2018
losses on sales and/or abandonment of property and equipment																																-15,000	22,000	212,000		58,000	15,000	29,000		68,000	16,000	37,000	367,000			91,000						28,000	-1,000	0	4,000	84,000	169,000	172,000	108,000	54,000	16,000	-4,000	205,000
excess tax benefits from stock-based compensation																																			-142,000	-539,000	9,000	3,000	-152,000	-552,000	-560,000	-860,000	-333,000	-7,000	-68,000	-168,000	-114,000	-21,000	-177,000	53,000	-1,593,000										339,000	50,000	372,000		47,000	263,000		38,000	46,000	132,000		147,000	192,000	169,000
proceeds from sale of cost method investment																																			0	0	0	1,089,000
issuance of notes receivable
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2018, 2017 and 2016
offering costs																											0
long-term debt issuance costs																																			0
payment of taxes related to an exchange of common stock																											0								0				0	-258,000	-280,000	-380,000	-29,000	0	0	-220,000	0	0			-152,000
beginning of year
end of year
cash paid during the year for:
contingent receivable in exchange for sale of equity investment
receivable for issuance of common stock associated with option exercises
merit common stock surrendered (43, 0 and 14 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiaries
consolidated statements of cash flows
for the nine months ended september 30, 2018 and 2017
merit common stock surrendered (43 and 0 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2018 and 2017
merit common stock surrendered (32 and 0 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2018 and 2017
losses (gains) on sales and/or abandonment of property and equipment
proceeds from sale-leaseback transactions																																							0	0	194,000	1,823,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2017, 2016 and 2015
cost method investment converted to intangible asset in acquisition in lieu of additional cash payment																																							0
contingent receivable in exchange for sale of cost method investment
merit common stock surrendered (0, 14 and 185 shares, respectively) in exchange for exercise of stock options
fair value changes in contingent liabilities/assets
employee receivables																																0	18,000	36,000	-27,000	-9,000	94,000	-43,000	-15,000	-57,000	26,000	-6,000	2,000	0	9,000	35,000	25,000	-51,000	-9,000	-18,000	67,000	26,000				22,000			11,000				8,000	3,000			-22,000	16,000	47,000	11,000				3,000
prepaid expenses and other assets																																-357,000	-1,459,000	229,000																													42,000			233,000											57,000
advances from employees																																368,000	-326,000	-86,000	47,000	69,000	269,000	-388,000	53,000	-98,000	-177,000	439,000	-457,000	228,000	-138,000	509,000	-441,000	22,000	52,000	90,000	-91,000	-566,000			15,000	-12,000	-343,000	-109,000	563,000		-23,000	105,000	105,000	71,000											-42,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2017 and 2016
payment of offering costs related to issuance of common stock																																-1,000	18,000	-833,000
merit common stock surrendered (0 and 14 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2017 and 2016
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2017 and 2016
prepaid expenses																																			723,000	1,774,000	-1,728,000	-498,000	-197,000	132,000	-471,000	-160,000	550,000	-242,000	285,000	-651,000	-56,000	-33,000	573,000	-1,242,000	1,334,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2016, 2015 and 2014
receivable due for sale of equipment
merit common stock surrendered (14, 185 and 127 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2016 and 2015
supplemental disclosure of non-cash investing and financing activities
contingent receivable received in exchange for sale of cost method investment																																				30,000	0	681,000
merit common stock surrendered (14 and 185 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2016 and 2015
acquisition purchases in accrued expenses
merit common stock surrendered (0 and 166 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2016 and 2015
merit common stock surrendered (0 and 89 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2015, 2014 and 2013
proceeds from industrial assistant grants																																															-511,000	150,000	0	750,000	705,000
net decrease in cash and cash equivalents																																							-1,682,000											-702,000
merit common stock surrendered (185, 127 and 45 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2015 and 2014
merit common stock surrendered (185 and 108 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2015 and 2014
merit common stock surrendered (166 and 108 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2015 and 2014
merit common stock surrendered (89 and 108 shares, respectively) in exchange for exercise of stock options																																										1,725,000
impairment of cost-method investment
realized gain on sale of marketable securities																																																			0
proceeds from the sale of marketable securities																																																			0					0
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2014, 2013 and 2012
net (decrease) in cash and cash equivalents
acquisition of customer list in exchange for a settlement of trade receivables																																																			-1,000
merit common stock surrendered (127, 45 and 131 shares, respectively) in exchange for exercise of stock options
proceeds from sale-leaseback transaction
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2014 and 2013
merit common stock surrendered (108 and 45 shares, respectively) in exchange for exercise of stock options																																												0
write-off of patents																																																	51,000	2,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2014 and 2013
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2014 and 2013
merit common stock surrendered (108 and 0 shares, respectively) in exchange for exercise of stock options																																														1,641,000
purchase of marketable securities
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2013, 2012 and 2011
merit common stock surrendered (45, 131 and 78 shares, respectively) in exchange for exercise of stock options
income tax refund receivable																																																-546,000	1,855,000	-782,000	193,000							103,000	16,000
patents and trademarks																																																-482,000	-267,000	-394,000		-309,000
cash paid in acquisitions																																																0	0	-1,000,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2013 and 2012
borrowings under long-term debt																																																39,053,000	36,973,000	34,199,000
supplemental disclosures of cash flow information:
supplemental disclosures of non-cash investing and financing activities:
merit common stock surrendered (45 and 71 shares, respectively) in exchange for exercise of stock options
changes in fair value of contingent consideration liability related to acquisitions
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2013 and 2012
supplemental disclosures of cash flow information —
merit common stock surrendered (45 and 103 shares, respectively) in exchange for exercise of stock options
excess tax benefit from stock-based compensation																																																		-53,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2013 and 2012
write-off of patents and license agreement
goodwill impairment charge
purchase of trading investments
unrealized gains on trading investments
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2012, 2011 and 2010
borrowings on line of credit
payments on line of credit
merit common stock surrendered (131, 78 and 0 shares, respectively) in exchange for exercise of stock options
(gain) loss on sales and/or abandonment of property and equipment
tax benefit attributable to appreciation of common stock options exercised																																																				-265,000																							693,000			536,186
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2012 and 2011
merit common stock surrendered (71 and 103 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2011, 2010 and 2009
common stock repurchased and retired
acquisition purchases in other long term obligations
merit common stock surrendered (78, 0 and 27 shares, respectively) in exchange for exercise of stock options
write-off of certain patents and trademarks																																																					42,000	3,000	14,000		84,000	0	24,000				27,000			40,000	150,000	60,000			0	0	0	40,000	36,000	15,000	14,000	209,507
impairment of goodwill
net unrealized losses on trading investments																																																															237,000
stock-based compensation																																																					436,000	311,000	335,000		344,000	302,000	304,000		305,000	277,000	298,000	293,000	239,000	98,000	371,000	363,000	249,000	147,000	306,000	432,000	374,000	390,000
income tax refunds receivable																																																																						3,000				955,000
liabilities related to unrecognized tax positions																																																																					166,000	163,000
other long-term assets
proceeds from sale of marketable securities
net unrealized gains on trading investments
write-off of certain patents and license agreement
unrealized (gains) losses on trading investments
current liabilities related to unrecognized tax benefits
non-current liabilities related to unrecognized tax benefits
net unrealized losses (gains) on trading investments
changes in operating assets and liabilities net of effects from acquisitions:
deposits																																																																			6,000	0	0	6,000	7,000
net unrealized (gains)/losses on trading investments
tax benefit attritutable to appreciation of common stock options exercised
excess tax benefit attributable to appreciation of common stock options exercised
proceeds from sale of trading investments
current liabilities related to unrecognized tax positions
non-current liabilities related to unrecognized tax positions
write-off of a certain patent and trademarks																																																													86,000
purchase of marketable securities available for sale
additions to long-term debt																																																													0
payment on long-term debt
supplemental disclosures of cash flow information—cash paid during the period for:
accrued purchase price																																																															533,000
net (decrease)/increase in cash and cash equivalents
proceeds from the sales of property and equipment																																																															5,000
supplemental disclosures of cashflow information—cash paid during the period for:
losses on sales and/or abandonment of equipment																																																																332,000	205,000	4,000		182,000	0	70,000
write-off of certain patents and a license agreement
sale (purchase) of trading investment securities
income tax benefit of options exercised
proceeds from the sale of equipment																																																																0				0
write-off of a certain patent and license agreement
increase in deferred compensation assets
proceeds from:
issuance of common stock																																																																				134,000	329,000	664,000				407,000	1,749,000	973,000	292,000	462,091
increase in deferred compensation payable																																																																				-129,000	72,000	81,000		7,000	-1,000	224,000	147,000	146,000	216,000
net cash from (used by) financing activities
net increase/(decrease) in cash and cash equivalents																																																																	2,999,000	6,183,000
decrease/(increase) in cash surrender value of life insurance contracts																																																																		52,000
proceeds from the sales of equipment																																																																		2,000				5,000				8,000
(decrease)/increase in deferred compensation payable
adoption of fin 48
impairment of assets
increase in cash surrender value of life insurance contracts
cash paid in acquisitions—net of cash acquired
other liabilities																																																																											-12,000	-12,000	137,000
principal payments on long-term debt
net cash (used by) provided by financing activities
net(decrease)/increase in cash and cash equivalents
note receivable
losses on sales and/or disposals of property and equipment
bad debt expense																																																																								57,000	0	24,000	11,000	-8,000	32,000	16,063
excess tax benefits for stock-based compensation
adjustments to reconcile net income to net cash
provided by operating activities:
losses (gains) on sales of property and equipment																																																																														-279
changes in operating assets and liabilities
net of effects from acquisitions:
net increase in cash and
cash equivalents
supplemental disclosures of cash
flow information—cash paid during
the period for:
losses on sales and abandonment of equipment																																																																										29,000
changes in operating assets and liabilities net of effects from acquisition:
other long-term obligation
cash paid in acquisition
losses on sales of property and equipment
changes in operating assets and liabilities:
net of effects from acquisition:
changes in operating assets and liabilities: net of effects from acquisition:
deferred credits
tax benefit attributable to appreciation of
common stock options exercised																																																																													36,000
employee and other receivables

We provide you with 20 years of cash flow statements for Merit Medical Systems stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Merit Medical Systems stock. Explore the full financial landscape of Merit Medical Systems stock with our expertly curated income statements.

The information provided in this report about Merit Medical Systems stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.